Remote Therapeutic Monitoring That Keeps Patients on Track telecare-usa.com Nov. 21, 2026, 8:16 a.m.
Remote Therapeutic Monitoring (RTM) through TeleCARE represents an innovative approach to extending clinical care beyond traditional scheduled appointments. Unlike Remote Patient Monitoring, which tracks physiological measurements such as blood pressure and glucose levels, RTM captures non-physiological data related to patient therapy and treatment progress. This information can be collected through connected medical devices or patient self-reporting, enabling providers to monitor treatment adherence, symptoms, and therapeutic response between visits. Healthcare practices implementing RTM gain enhanced visibility into patient progress, allowing earlier identification of potential concerns and timely treatment plan adjustments. The platform supports patients undergoing treatment for various chronic conditions and mental health issues. RTM eligibility and coverage vary based on patient factors, treatment type, provider credentials, and payer requirements. The service model provides monthly recurring revenue through CPT code billing, with reimbursement rates varying by geography based on national averages. By facilitating continuous patient engagement and proactive monitoring, RTM enables practices to deliver more connected, responsive care while capturing appropriate revenue for remote monitoring services rendered.
Regulatory Compliance of AI-Enabled Medical Devices in Asia-Pacific qservegroup.com Nov. 21, 2026, 8:16 a.m.
Manufacturers seeking to commercialize AI-enabled medical devices in Asia-Pacific face distinct regulatory challenges across six key markets: South Korea, Japan, Vietnam, Singapore, Australia, and Malaysia. Each jurisdiction maintains unique medical device frameworks, market-access pathways, and approaches to emerging technologies, requiring careful strategic planning beyond the established EU and US regulatory landscapes. South Korea has emerged as an attractive market given its advanced healthcare infrastructure and technological capabilities, governed by the Medical Device Act and newly implemented Digital Medical Products Act (2025). The Ministry of Food and Drug Safety has issued pioneering guidance on AI-based device approval and clinical trial design, including the world's first generative AI medical device guideline (2025). The AI Basic Act, effective 2026, provides additional horizontal AI governance. Manufacturers must understand how AI integrates into devices, validate performance, manage changes, and monitor safety throughout the product lifecycle. Demonstrating that AI-enabled devices function effectively is now insufficient; regulatory compliance requires comprehensive documentation of AI incorporation, validation methodologies, and post-market surveillance strategies. This multifaceted approach ensures patient safety while facilitating market entry across diverse Asia-Pacific regulatory environments.
Medical Software Certification & Cybersecurity Testing tuv.com Nov. 21, 2026, 8:16 a.m.
The global medical technology market is projected to reach $800 billion by 2030, growing at an annual rate of 2.68%, driving increased demand for regulatory compliance and cybersecurity assurance. TÜV Rheinland, operating across 50+ countries, offers comprehensive end-to-end certification services verifying compliance with critical standards including IEC 62304, IEC 81001-5-1, IEC 60601-4-5, alongside MDR, IVDR, and FDA requirements. The organization provides specialized cybersecurity testing encompassing penetration testing, vulnerability scanning, fuzz testing, and Threat Analysis and Risk Assessment (TARA) to protect medical devices against evolving threats to patient data and device performance. With 15,600+ medical technology patent applications filed in Europe in 2022 alone, the accelerating innovation landscape necessitates rapid market access. TÜV Rheinland's structured verification and validation testing aligns with regulatory submission timelines, enabling manufacturers to navigate multi-region approvals efficiently. Through independent reporting and global expertise combined with local regulatory knowledge, the organization delivers impartial assessments identifying vulnerabilities in software-driven medical devices, from wearables to networked hospital systems, supporting manufacturers in bringing secure innovations to market faster.
IEC 62304 Explained: The Medical Device Software Standard medqair.com Nov. 21, 2026, 8:16 a.m.
IEC 62304, the international standard for medical device software lifecycle management, was first published in 2006 with Amendment 1 in 2015, with the consolidated edition 1.1 recognized by the FDA on January 14, 2019 (recognition number 13-79), though it does not currently appear on the EU's MDR harmonised standards list. The standard defines lifecycle requirements applicable to software that functions as a medical device or is embedded within one, excluding final device validation which requires separate evidence. As a process standard rather than a prescriptive methodology, IEC 62304 is compatible with Agile development provided required tasks are documented. It operates within quality management systems (ISO 13485) and risk management frameworks (ISO 14971). The standard classifies software into safety classes based on risk, with Class C requiring the most rigorous documentation in architecture, design, and verification. Clause 5 encompasses the complete development cycle from planning through release, while Clause 6 addresses maintenance—a critical phase representing the majority of software lifecycle duration. The classification rationale, including external risk control dependencies, must be recorded and revisited if intended use or interfaces change.
Remote Therapeutic Monitoring (RTM) for PT Clinics: 2026 Codes, Rates and 2027 Changes www.spryhealth.ai Nov. 21, 2026, 8:16 a.m.
Remote therapeutic monitoring (RTM) has emerged as a valuable Medicare-recognized service enabling physical therapists, occupational therapists, and speech-language pathologists to monitor patient-reported data between visits and generate billable claims. The Centers for Medicare and Medicaid Services (CMS) introduced RTM codes in 2022 and significantly expanded the offering for 2026 with four new CPT codes, including a novel 2 to 15-day device supply code priced equivalently to the existing 16 to 30-day code. For musculoskeletal RTM, a complete 30-day monitoring period using codes 98977 and 98980 carries a national Medicare allowed amount of approximately $105.55 per patient in 2026, with setup code 98975 adding a one-time charge of $21.71. SPRY's RTM software, integrated into its Plus and Billing Service plans, leverages Wibbi activity data to track transmission-day counts and automate code selection, streamlining claims preparation once billing thresholds are achieved. Billing rules require practitioners to submit one device supply code per patient per 30-day period based on transmission days, while treatment management codes depend on documented real-time interactive communication duration. These reimbursement rates are subject to locality adjustments and will change in 2027, making ongoing verification through CMS resources essential for accurate billing.
How Do I Actually Prescribe an FDA-Cleared Digital Therapeutic to My Patient? residencyadvisor.com Nov. 10, 2026, 11:24 p.m.
Digital therapeutics represent a distinct category of prescription medical devices that differ fundamentally from wellness apps or step counters. These software-based interventions have undergone rigorous clinical trials, demonstrated measurable efficacy, and received FDA regulatory clearance to treat, manage, or prevent specific diseases. The regulatory distinction between FDA clearance and approval is critical for clinicians to understand. Most digital therapeutics currently on the market are FDA-cleared through the 510(k) or De Novo pathways, determining they are safe and substantially equivalent to predicate devices or safe and effective for novel, low-to-moderate risk uses, rather than approved through the more rigorous Premarket Approval pathway reserved for high-risk devices. As digital therapeutics have transitioned from experimental technology to standard-of-care adjuncts, prescribing them now carries the same clinical weight, legal liability, and ethical responsibility as prescribing controlled substances or biologics. Clinicians must identify the exact indication, verify regulatory status, assess patient suitability, execute formal prescription workflows, and monitor adherence data. Before prescribing, clinicians must verify the specific disease indication for which the software is cleared, as misalignment between the cleared indication and actual use can result in severe compliance audits.
Wearable Technologies for Sleep Disorder Screening and Monitoring: Sensors, Clinical Validation and Future Directions www.intechopen.com Nov. 10, 2026, 11:23 p.m.
Wearable technologies are revolutionizing sleep medicine by enabling long-term home monitoring of physiological and behavioral signals traditionally assessed only in laboratory sleep studies. This comprehensive review examines wearable devices for screening and monitoring sleep disorders including obstructive sleep apnea (OSA), circadian rhythm sleep-wake disorders (CRSWDs), and insomnia. The analysis covers multiple sensor technologies—accelerometers, gyroscopes, photoplethysmography (PPG), oxygen saturation monitors, bioimpedance measurement, electrocardiography (ECG), respiration, temperature, and bioelectrical activity sensors—used to record digital sleep biomarkers. Various device form factors are evaluated, including watches, rings, patches, respiratory belts, headbands, neck-worn modules, mask-mounted systems, smart clothing, and hybrid architectures. The chapter addresses engineering challenges and design limitations while exploring future development directions. Importantly, wearable sleep monitoring technologies are positioned as complementary tools to polysomnography rather than replacements, expanding access to sleep assessment and enabling more personalized, reproducible, and clinically meaningful monitoring across diverse patient populations.
The FDA AI/ML SaMD Framework: What Companies Need to Know Now www.berkleyls.com Nov. 10, 2026, 11:23 p.m.
The FDA has established a comprehensive regulatory framework for artificial intelligence and machine learning-enabled software as medical devices (SaMD), with over 1,400 such devices authorized for U.S. marketing as of December 2025, predominantly through the 510(k) pathway. Following its January 2021 AI/ML Action Plan introducing a total product lifecycle approach, the agency has evolved its oversight strategy through collaborative efforts with Health Canada and the UK's MHRA, resulting in jointly published Good Machine Learning Practice principles adopted by the International Medical Device Regulators Forum in January 2025. The FDA's newly finalized Predetermined Change Control Plans framework enables manufacturers to proactively specify anticipated device modifications rather than rely on passive monitoring. In January 2025, the agency released two draft guidances addressing lifecycle management and a risk-based credibility framework developed from reviewing over 500 regulatory submissions containing AI components. This iterative regulatory maturation matters significantly for companies developing AI/ML-enabled medical devices, as it shifts expectations from reactive post-market compliance to strategic pre-market planning, clarifying pathways for devices capable of learning and adapting after deployment.
Software as a Medical Device (SaMD): FDA and EU Guide www.greenlight.guru Nov. 10, 2026, 11:23 p.m.
Software as a Medical Device (SaMD) encompasses standalone software designed to diagnose, monitor, analyze, or inform medical treatment decisions using health data and patient information, distinguished from software embedded in physical hardware devices (SiMD). The IMDRF and FDA define SaMD as software performing medical purposes independently from hardware devices. Development teams must navigate complex regulatory frameworks including FDA approval, EU MDR, IEC 62304, ISO 13485, and ISO 14971 standards. Critical considerations include intended use determination, risk classification, software lifecycle processes, cybersecurity measures, clinical evaluation requirements, and AI/ML controls where applicable. The regulatory landscape surrounding SaMD presents significant challenges for software-focused teams unfamiliar with medical device requirements. Understanding whether a healthcare software product qualifies as SaMD depends primarily on its intended medical purpose and independence from hardware components. Recent developments in 2025–2026 and the EU AI Act further shape compliance obligations, making comprehensive knowledge of SaMD classification, global regulations, and development requirements essential for successful market entry and regulatory approval.
Remote Therapeutic Monitoring Support myseema.com Nov. 3, 2026, 1:21 p.m.
Remote Therapeutic Monitoring (RTM) represents an approach to enhance patient care by coordinating medication and treatment adherence without requiring a separate administrative department. The system helps patients understand their monitoring plans, addresses participation barriers, and documents activities while routing clinical concerns to treating physicians. RTM employs various device options tailored to specific therapies, including medication compartment and bottle-opening trackers for pillboxes, inhaler-use monitoring systems, and patient-reported outcome measures for pain and function. MySeema coordinates support services while qualified clinicians retain treatment direction. The framework emphasizes that device selection must align with prescribed therapy, patient routines, and applicable monitoring pathways; notably, opening a medication container does not confirm actual dose consumption, and inhaler events alone cannot validate proper technique. CMS billing includes qualifying management time with interactive communication requirements, with codes such as 98980 applicable for RTM management exceeding twenty minutes per eligible patient. Reimbursement varies based on location, setting, clinician type, and coverage parameters. This structured approach aims to improve treatment outcomes by supporting adherence monitoring while maintaining clinical oversight and appropriate documentation standards.
Patient engagement strategies that actually work in private clinics pabau.com Nov. 3, 2026, 1:21 p.m.
Patient engagement transforms patients from passive care recipients into active participants in managing their health, with evidence showing this approach significantly improves outcomes. Research from the CDC and NCBI identifies the highest-evidence strategies as group-based chronic disease education, SMS and web-based interventions, and telehealth-supported self-monitoring. A critical challenge in private clinics is patient retention between visits rather than during them; automated recall systems, post-care follow-up, and patient portal access emerge as the most effective retention tools. Private clinics and aesthetic practices lose an estimated 20-30% of their active patient base annually, often through passive drift rather than competitor defection. Platforms like Pabau address this by automating recall workflows, delivering pre- and post-care instructions, and providing self-service portals, reducing manual team effort. The Patient Activation Measure, a validated scale measuring patient activation levels, demonstrates that higher activation correlates with lower hospitalization rates, better chronic disease management, and improved treatment adherence. Rather than treating patient engagement as a marketing challenge, successful clinics embed evidence-based engagement strategies throughout their operational workflows, from pre-visit intake through post-visit follow-up, making engagement a sustainable operational priority that increases patient retention without expanding staffing needs.
Remote Therapeutic Monitoring: Revolutionizing Healthcare www.spryhealth.ai Nov. 3, 2026, 1:21 p.m.
Remote therapeutic monitoring powered by wearable devices is transforming how physical therapists, occupational therapists, and speech-language pathologists deliver care. Wearable technologies—from smartwatches to specialized sensors—provide real-time data on patient activity, movement, and progress, enabling therapists to tailor interventions effectively. Telehealth platforms facilitate virtual therapy sessions across rehabilitation exercises, cognitive activities, and speech therapy, while integration of virtual and augmented reality creates immersive, engaging experiences. Artificial intelligence and machine learning algorithms analyze vast patient datasets to identify patterns, predict complications, and personalize treatment plans by assessing movement, cognitive function, and speech patterns. Security and privacy protection remain critical priorities, requiring advanced encryption and compliance with healthcare regulations. Patient engagement is enhanced through interactive applications and gamification elements that motivate active participation in therapy. Sophisticated outcome measurement tools and analytics provide data-driven insights, allowing therapists to track progress, make informed adjustments, and demonstrate intervention effectiveness. Collectively, these technologies address traditional care limitations by delivering continuous monitoring of patient activity and health status, revolutionizing therapeutic practice.
What is the Difference Between RPM and RTM? www.limberhealth.com Nov. 3, 2026, 1:20 p.m.
Remote therapeutic monitoring (RTM) and remote physiologic monitoring (RPM) represent distinct virtual care modalities designed for different clinical purposes within hybrid rehabilitation therapy. While RPM tracks physiological data such as weight, blood pressure, and pulse oximetry for chronic disease management by physicians and certain non-physician practitioners, RTM monitors non-physiological data including therapy adherence, patient engagement, and musculoskeletal treatment response between clinical visits. RTM emerged as a Medicare-approved care model in response to a gap identified during the COVID-19 pandemic, when RPM codes proved valuable for physicians but excluded musculoskeletal, respiratory, and cognitive behavioral therapy providers. The American Medical Association's CPT Editorial Panel introduced RTM-specific codes in late 2020, which received CMS approval and went live in 2022. RTM primarily supports musculoskeletal rehabilitation, respiratory therapy, and cognitive behavioral therapy by monitoring subjective metrics and behavioral markers reflecting how patients manage recovery at home. Understanding these distinctions enables physical and occupational therapy practices to select the appropriate monitoring model for their patient populations and operational workflows, optimizing virtual care pathways and treatment outcomes.
Software as a Medical Device (SaMD): FDA Pathways www.leverventure.com Nov. 3, 2026, 1:20 p.m.
Software as a Medical Device (SaMD) represents software designed for medical purposes that operates independently of hardware devices, as defined by the International Medical Device Regulators Forum (IMDRF). The FDA categorizes SaMD as one of three software types related to medical devices, governed by the Federal Food, Drug, and Cosmetic Act. A significant regulatory framework emerged from the 21st Century Cures Act (enacted December 13, 2016), which added section 520(o) to establish exemptions for clinical decision support (CDS) software meeting four specific criteria: it must not analyze medical images or diagnostic signals, must display or analyze medical information, must support healthcare professional recommendations, and must allow independent professional review of recommendations. The FDA reissued its SaMD guidance on January 29, 2026, clarifying enforcement positions regarding single-option recommendations and patient-directed software. The IMDRF risk framework categorizes SaMD into four risk categories based on healthcare decision significance and situation acuity, with Category IV representing highest impact. Device authorization occurs through three FDA pathways: the 510(k) premarket notification route, De Novo classification for novel devices, or the traditional premarket approval process for Class III devices, enabling appropriate regulation based on risk levels.
The Last Mile of Digital Implementation: A Technical Framework for Turning Clinical Technology Adoption Into Measurable Value drug-dev.com Oct. 24, 2026, 7:26 a.m.
Digital health implementation in clinical trials has evolved beyond technical deployment to focus on actual operational value realization. While platforms meeting FDA guidance on remote data acquisition, decentralized trial elements, and electronic systems—alongside ICH E6(R3) standards—represent necessary technical achievement, they frequently fail to deliver meaningful outcomes if poorly integrated into workflows or inconsistently adopted. Dr. Harsh Shah proposes a five-layer framework addressing this "last mile" implementation challenge: Technical Fitness, Workflow Fit, Adoption, Data Reliability, and Outcome Conversion. Traditional success metrics measuring configuration completion, validation passage, and site activation mask deeper failures, such as electronic clinical outcome assessment platforms deployed to all sites yet generating high participant support needs and parallel paper workarounds, or analytics platforms producing unactionable alerts. Shah's diagnostic model—Realized Value equals the multiplication of all five layers—demonstrates that weakness in any single component compromises overall value delivery. This framework shifts evaluation emphasis from binary go-live milestones toward sustained measurement of whether technology genuinely improves trial execution and decision-making, establishing necessary standards for mature digital implementation in drug development.
Digital Phenotyping for Mental Health Monitoring and Personalized Prediction in People with Diabetes www.frontiersin.org Oct. 24, 2026, 7:26 a.m.
Researchers from Chinese universities conducted a scoping review examining how digital phenotyping technologies can monitor and predict mental health outcomes in people with diabetes. The review searched six English and four Chinese databases through September 2026, ultimately analyzing ten studies. The evidence reveals that digital phenotyping enables real-time mental health monitoring through continuous glucose monitoring devices, passive smartphone sensing, voice analysis, and ecological momentary assessment. Machine learning algorithms were commonly employed for risk prediction modeling; however, most studies operated at the group level rather than individual level, with limited use of n-of-1 analysis or subgroup prediction for personalized outcomes. The review identified significant gaps, including insufficient external validation of models and an absence of intervention studies. Given that depression, anxiety, and diabetes-related distress frequently co-occur and directly impact glycemic control and complication risk, this technology offers promising potential for more objective, real-time mental health assessment compared to traditional subjective scales. Future development should prioritize individualized risk prediction models, robust validation protocols, and intervention trials to fully realize digital phenotyping's clinical utility in diabetes care.
Patient engagement strategies: Developing patient companion apps for long-term adherence star.global Oct. 24, 2026, 7:26 a.m.
Digital health app engagement remains a critical challenge, with industry benchmarks revealing that approximately fifty percent of users remain active after thirty days, declining to just one in five after a year. This engagement problem extends beyond mere app retention metrics, significantly impacting patient outcomes and clinical effectiveness. When patients perceive that tracking effort outweighs perceived benefits—particularly with repetitive reminders, manual data entry, and limited feedback—disengagement follows, leading to missed treatment actions, reduced clinician visibility between appointments, and lost patient-generated data valuable for real-world evidence. Successful patient companion app development requires embedding engagement strategies from inception rather than treating them as afterthoughts. Effective approaches must account for evolving patient motivations, integration with daily routines, caregiver involvement, alignment with clinical workflows, and clear evidence requirements. This comprehensive design perspective transforms patient engagement from a retention metric into a fundamental design challenge, ensuring digital health products deliver sustained value throughout patients' treatment journeys.
ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model www.cms.gov Oct. 24, 2026, 7:26 a.m.
The Centers for Medicare & Medicaid Services has launched the ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) Model, a voluntary 10-year initiative beginning July 5, 2026, designed to expand technology-supported chronic care delivery for Medicare beneficiaries. The program addresses chronic conditions affecting over two-thirds of Medicare enrollees, including hypertension, diabetes, chronic musculoskeletal pain, and depression. ACCESS introduces Outcome-Aligned Payments (OAPs), a novel reimbursement approach that provides participating organizations recurring payments for managing qualifying conditions, with full compensation contingent upon achieving measurable health outcomes. This addresses a critical gap in Original Medicare's fee-for-service model, which historically cannot adequately support technology-enabled care delivery. New disease tracks for heart failure, COPD, substance use disorder, tobacco cessation, and chronic musculoskeletal pain launch April 1, 2027. Leading medical societies and major health plans have pledged support for ACCESS-aligned payment options. The model particularly benefits patients in underserved communities with limited local care access, including rural areas, by enabling continuous digital health support beyond traditional office visits.
Building Trust: The APEC Blueprint For A Sovereign, AI-Powered Mental Health Ecosystem • EMHIC emhicglobal.com Oct. 24, 2026, 7:25 a.m.
The article examines the urgent need for a sovereign approach to artificial intelligence in healthcare, beginning with a diagnosis of systemic failures in centralized digital platforms. Drawing on Cory Doctorow's concept of "platform enshitification," the piece describes how digital health ecosystems have become extractive silos that undermine patient agency and erode trust through data breaches and behavioral manipulation. In response, the "Building Together" platform has been developed as a sovereign mental health ecosystem designed to address these vulnerabilities. The article emphasizes that rapid AI advancement—exemplified by Anthropic's Claude Mythos 5 deployment through Project Glasswing—is outpacing regulatory strategies and fundamentally threatening traditional cybersecurity for healthcare data. The Mythos model's capacity for autonomous vulnerability discovery and network reconnaissance has rendered centralized firewall protections obsolete. Consequently, healthcare systems must transition toward decentralized, cryptographically verifiable trust frameworks managed at the data source. Canadian technology leaders Don and Alex Tapscott have advocated for establishing a national digital identity framework to help the nation adapt to this technological shift, highlighting the critical importance of building resilient healthcare infrastructure.
Digital Interventions for ADHD: Pediatric Meta-Analysis www.omnicuris.com Oct. 17, 2026, 7:18 a.m.
Attention-deficit/hyperactivity disorder affects millions of school-aged children globally, presenting with inattention, executive dysfunction, and motor impulsivity that often lead to academic underachievement and social difficulties. While pharmacotherapy remains a primary treatment approach, concerns about adverse effects like appetite suppression and growth inhibition, combined with limited access to specialized behavioral therapies, have prompted exploration of alternative interventions. A comprehensive meta-analysis synthesizing thirty-seven randomized controlled trials examined digital therapeutics as scalable treatment options for pediatric ADHD. The analyzed interventions included four technological categories: computer-based cognitive programs, serious video games, exergames, and virtual reality environments. Unlike passive screen use, these structured digital tools leverage neuroplasticity through adaptive cognitive stimulation and closed-loop feedback mechanisms, potentially modulating dopaminergic pathways to improve attention spans without pharmacologic toxicity. The pooled evidence demonstrates statistically significant improvements in both core ADHD symptoms and broader neuropsychological performance metrics. These findings are particularly significant as digital therapeutics offer objective behavioral tracking, scalability across diverse settings, and accessible alternatives to traditional treatment modalities, representing a valuable complement to existing clinical approaches in pediatric ADHD management.